[治疗具有HER2变异的非小细胞肺癌]
Toshiaki Takakura1, Nobuyuki Yamamoto
1Internal Medicine Ⅲ , Wakayama Medical University.
Gan to kagaku ryoho. Cancer & chemotherapy
|July 27, 2023
概括
非小细胞肺癌 (NSCLC) 的HER2变异越来越多地成为治疗的目标. 特拉斯图祖马布-德鲁克斯坦 (T-Dxd) 对特定的HER2突变显示出显著的疗效,提供了新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 与乳腺癌和胃癌相比,HER2变异在非小细胞肺癌 (NSCLC) 中具有明显的治疗机会.
- 在HER2中发生的基因突变是NSCLC治疗的关键焦点,与其他癌症的基因放大和蛋白质过度表达目标不同.
- 从历史上看,对于患有HER2变异的NSCLC患者,存在有限的有效治疗方法.
研究的目的:
- 审查 HER2 改变的 NSCLC 的治疗前景.
- 突出针对性疗法和抗体-药物合物的最新进展.
- 讨论新的治疗方案的临床意义.
主要方法:
- 关于NSCLC中的HER2变异研究的文献综述.
- 对向疗法和抗体-药物合物的临床试验数据的分析.
- 对相关治疗方法的FDA批准状况的审查.
主要成果:
- 铁氨酸激酶抑制剂 (TKIs),如皮洛替尼和定替尼,显示出抗瘤活性.
- 抗体-药物联结物 (ADC),特别是特拉斯图祖马布-德鲁克斯坦 (T-DXd),显示出显著的疗效.
- 在2022年8月,T-DXd获得了FDA的批准,用于NSCLC中的特定HER2突变.
结论:
- 向疗法,特别是ADCs,代表了对HER2-改变的NSCLC的重大进展.
- 特拉斯图祖马布-德鲁克斯坦为一组NSCLC患者提供了一个有前途的新疗法选择.
- 对HER2向治疗的进一步研究是有必要的,以改善患者的治疗结果.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.1K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
558
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
206
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
206
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
